EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Significance of HPV status on tumor response and treatment outcomes in endocervical adenocarcinoma treated with definitive chemoradiotherapy: a retrospective study

Jong Yun Baek iD, Hyun-Soo Kim iD, Won Kyung Cho iD, Byoung-Gie Kim iD, Jeong-Won Lee iD, Chel Hun Choi iD, Tae-Joong Kim iD, Yoo-Young Lee iD, Won Park iD

Journal of Gynecologic Oncology · 2025

DOI: 10.3802/jgo.2025.36.e92 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gynecologic Oncology, 2025. Verfasst von Jong Yun Baek und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Adenocarcinoma, Chemoradiotherapy, Papillomavirus Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: SMC, NRF, Samsung Medical Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: We aimed to compare tumor response and treatment outcomes between human papillomavirus (HPV)-associated (HPVA) and HPV-independent (HPVI) endocervical adenocarcinomas (ADCs) treated with definitive concurrent chemoradiotherapy (CCRT) and to identify prognostic factors. METHODS: We conducted a retrospective review of 40 patients with endocervical ADCs treated with definitive CCRT (stages I-IVA) between 2011 and 2022. Based on pathological review the cases were categorized as HPVA or HPVI ADCs. Statistical analyses were performed to compare the characteristics, complete response (CR) rates, and survival outcomes. RESULTS: Of 40 patients, 22 (55.0%) had HPVA and 18 (45.0%) had HPVI ADCs. HPVI patients had significantly higher rates of parametrial invasion (94.4% vs. 45.5%, p=0.001). CR was achieved in 57.5% of patients and was significantly more common in the HPVA group (81.8% vs. 27.8%, p=0.001). Patients with HPVI had higher recurrence rates (88.9% vs. 50.0%, p=0.016) and lower 3-year progression-free survival (PFS, 16.7% vs. 49.8%, p=0.001), distant metastasis-free survival (DMFS, 38.1% vs. 80.8%, p=0.001), and overall survival (OS, 42.3% vs. 90.7%, p=0.002) rates. HPVA remained a significant factor for PFS (hazard ratio [HR]=3.44; 95% confidence interval [CI]=1.09-10.81; p=0.035) and OS rates (HR=6.83; 95% CI=1.17-39.80; p=0.033) in multivariate analysis. CONCLUSION: HPVI ADC was associated with a lower response to definitive CCRT and worse prognosis than HPVA ADC. These findings suggest the need for tailored treatment strategies based on the HPV status.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsAdenocarcinomaChemoradiotherapyPapillomavirus InfectionsHumansFemaleRetrospective StudiesMiddle AgedAdultAgedTreatment OutcomePrognosisNeoplasm Recurrence, LocalPapillomaviridae

Stichwörter der Autor:innen

AdenocarcinomaHuman PapillomavirusRadiotherapyUterine Cervical Neoplasms

Autor:innen und Institutionen

  • Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. wonro.park@samsung.com.

ORCID-Profile: Jong Yun Baek, Hyun-Soo Kim, Won Kyung Cho, Byoung-Gie Kim, Jeong-Won Lee, Chel Hun Choi, Tae-Joong Kim, Yoo-Young Lee, Won Park

Förderung

  • SMC
  • NRF
  • Samsung Medical Center
  • National Research Foundation of Korea

Zitieren

APA

Baek, J. Y., Kim, H. S., Cho, W. K., Kim, B. G., Lee, J. W., Choi, C. H., Kim, T. J., Lee, Y. Y., & Park, W. (2025). Significance of HPV status on tumor response and treatment outcomes in endocervical adenocarcinoma treated with definitive chemoradiotherapy: a retrospective study. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2025.36.e92

Vancouver

Baek JY, Kim HS, Cho WK, Kim BG, Lee JW, Choi CH, et al. Significance of HPV status on tumor response and treatment outcomes in endocervical adenocarcinoma treated with definitive chemoradiotherapy: a retrospective study. Journal of Gynecologic Oncology. 2025. doi:10.3802/jgo.2025.36.e92

BibTeX
@article{Baek2025,
  author = {Baek, Jong Yun and Kim, Hyun-Soo and Cho, Won Kyung and Kim, Byoung-Gie and Lee, Jeong-Won and Choi, Chel Hun and Kim, Tae-Joong and Lee, Yoo-Young and Park, Won},
  title = {Significance of HPV status on tumor response and treatment outcomes in endocervical adenocarcinoma treated with definitive chemoradiotherapy: a retrospective study},
  journal = {Journal of Gynecologic Oncology},
  year = {2025},
  doi = {10.3802/jgo.2025.36.e92}
}
Kostenlos starten →